DGAD recommends anti-dumping duty on amoxycillin imports from China
The Dollar Business Bureau
Directorate of Anti-Dumping & Allied Duties (DGAD) has recommended imposition of anti-dumping duty on the imports of amoxycillin from China PR in order to remove the impact of injury caused to domestic industry due to cheap imports.
Amoxycillin, also known as Amoxicillin Trihydrate, is a semisynthetic antibiotic, an analog of ampicillin, with a broad spectrum of bactericidal activity against many Gram-positive and Gram-negative microorganisms and is used to reduce the development of drug-resistant bacteria.
The DGAD has found sufficient evidence of dumping of amoxycillin from China and recommended imposition of anti-dumping duty equal to the lesser of the margin of dumping and margin of injury so determined, so as to remove the injurious effects of the dumped imports on the domestic industry.
“After examining the issues raised and submissions made by the interested parties and facts made available before the Authority, as recorded in this finding, the Authority concludes that the subject goods are entering the Indian market from the subject country at dumped prices and performance of the domestic industry has deteriorated in the injury period due to the impact of the dumped imports from the subject country. The injury suffered by the domestic industry is significant and material,” DGAD said in a notification (F.No.14/05/2015-DGAD) on Monday.
“Therefore, the Authority considers it necessary and appropriate to recommend imposition of anti-dumping duty on imports of subject goods, from the subject country,” it said.
“Having regard to the lesser duty rules followed, the Authority recommends imposition of anti-dumping duty equal to the lesser of the margin of dumping and margin of injury,” it added.
Anti-dumping duty is recommended to be imposed for a period of five years from the date of notification to be issued in this regard by the Central Government, the notification said.
However, the following types of products are excluded from the scope of the product under consideration: Amoxycillin Sodium Sterile and Flucloxacillin Sodium Sterile, Amoxicillin Trihydrate Compacted Ampicillin Trihydrate Compacted and Amoxicillin Trihydrate and Clavulanate Potassium.
The period of investigation was from 2011-12 to 2014-15.
The application has been filed by Aurobindo Pharma Ltd, which is a domestic producer of the product under consideration in India.